Active Ingredient History
Basiliximab, sold under the brand name Simulect, is a monoclonal antibody used to prevent rejection in kidney transplants. It is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used in combination with other medicines used to prevent organ rejection. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Kidney Diseases (approved 1998)
Allografts (Phase 2)
Amyotrophic Lateral Sclerosis (Phase 2)
Anemia, Aplastic (Phase 2)
beta-Thalassemia (Phase 4)
Brain Neoplasms (Phase 1)
Colitis, Ulcerative (Phase 2)
Corneal Transplantation (Phase 2)
COVID-19 (Phase 2)
Cytokine Release Syndrome (Phase 2)
Cytomegalovirus Infections (Phase 4)
Dermatomyositis (Phase 2)
Diabetes Mellitus, Type 1 (Phase 3)
Diabetic Nephropathies (Phase 4)
Emphysema (Phase 3)
Everolimus (Phase 2/Phase 3)
Glioblastoma (Phase 2)
Glomerulonephritis (Phase 4)
Graft Rejection (Phase 4)
Graft vs Host Disease (Phase 2)
Hemoglobinuria, Paroxysmal (Phase 2)
Hodgkin Disease (Phase 2)
Infections (Phase 3)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 4)
Kidney Tubular Necrosis, Acute (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Liver Cirrhosis (Phase 4)
Liver Transplantation (Phase 4)
Lung Diseases (Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Organ Transplantation (Phase 2)
Ovulation Induction (Phase 4)
Primary Myelofibrosis (Phase 2)
Prostatic Neoplasms (Phase 3)
Pulmonary Disease, Chronic Obstructive (Phase 3)
Renal Insufficiency, Chronic (Phase 4)
Reperfusion Injury (Phase 3)
Sclerosis (Phase 2)
Uremia (Phase 1/Phase 2)
Uveitis (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
